TEMPEST THERAPEUTICS INC (TPST) Stock News

NASDAQ:TPST - Nasdaq - US87978U2078 - Common Stock - Currency: USD

8.5 +0.49 (+6.12%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TPST Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Tempest Therapeutics

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

a day ago - By: Tempest Therapeutics

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Tempest Therapeutics

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

a month ago - By: Tempest Therapeutics

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

2 months ago - By: Benzinga - Mentions: SSY HSDT WINT NCNA ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

2 months ago - By: Tempest Therapeutics

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

2 months ago - By: Tempest Therapeutics

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

2 months ago - By: Benzinga - Mentions: OMH ELAB GHM KLTO ...

Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

2 months ago - By: Zacks Investment Research - Mentions: LXRX CMMB

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

2 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

3 months ago - By: Tempest Therapeutics

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Tempest Therapeutics

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Tempest Therapeutics

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

4 months ago - By: Tempest Therapeutics

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

4 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

4 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

4 months ago - By: Tempest Therapeutics

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

4 months ago - By: Tempest Therapeutics

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

5 months ago - By: Tempest Therapeutics

Tempest Reports Year End 2024 Financial Results and Provides Business Update

5 months ago - By: Tempest Therapeutics

Tempest Reports Year End 2024 Financial Results and Provides Business Update

5 months ago - By: Tempest Therapeutics

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

5 months ago - By: Tempest Therapeutics

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

5 months ago - By: Tempest Therapeutics

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

5 months ago - By: Tempest Therapeutics

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

6 months ago - By: Tempest Therapeutics

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

6 months ago - By: Tempest Therapeutics

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

6 months ago - By: Tempest Therapeutics

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Tempest Therapeutics

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

7 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

8 months ago - By: Tempest Therapeutics

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Tempest Therapeutics

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)